NCT06637527View on ClinicalTrials.gov

The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain

PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

July 1, 2025

Conditions
Neuropathic Pain
Interventions
DRUG

OK-101 0.05%

0.05% Ophthalmic Solution

DRUG

OK-101 0.1%

0.1% Ophthalmic Solution

DRUG

Placebo

Placebo

Trial Locations (1)

02111

Tufts Medical Center, Boston

Sponsors

Lead Sponsor

Okyo Pharma Ltd
All Listed Sponsors
collaborator

Tufts Medical Center

OTHER

lead

Okyo Pharma Ltd

INDUSTRY

NCT06637527 - The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain | Biotech Hunter | Biotech Hunter